Edwards Lifesciences Corporation EW
86.29
0.56
0.65%
as of 25 Sep
- Market cap
- $49.4B
- P/E
- 49.6×
Follow EW
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Edwards Lifesciences Corporation (EW) Net margin
Edwards Lifesciences Corporation's net margin over the twelve months to 30 June 2026 was 15.4%, down 2.3 percentage points from fiscal 2025 (17.7%). Over the past ten years it has ranged from 17.0% (fiscal 2017) to 76.8% (fiscal 2024); the current reading is higher than 18% of that period. That is above the Medical Devices industry median of −20.4% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 17.7% | (59.06) |
| FY2024 | 76.8% | 48.76 |
| FY2023 | 28.0% | (6.10) |
| FY2022 | 34.1% | 5.36 |
| FY2021 | 28.7% | 9.96 |
| FY2020 | 18.8% | (5.31) |
| FY2019 | 24.1% | 4.68 |
| FY2018 | 19.4% | 2.41 |
| FY2017 | 17.0% | (2.23) |
| FY2016 | 19.2% | (0.63) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 13.9% | (9.20) |
| Mar 2026 | 23.1% | 17.28 |
| Dec 2025 | 5.81% | (12.93) |
| Sep 2025 | 18.7% | (3.01) |
| 42 more quarters | Free account |
Against its own ten years
Low 17.0%
High 76.8%
Ten-year median
19.9%
Current reading's percentile
18
Net margin against peers
| Company | Net margin |
|---|---|
| DXCM DexCom, Inc. compare | 20.1% |
| BSX Boston Scientific Corporation compare | 17.5% |
| EW Edwards Lifesciences Corporation | 15.4% |
| SYK Stryker Corporation compare | 14.4% |
| MDT Medtronic PLC compare | 13.9% |
| STE STERIS plc compare | 13.3% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 9.48% |
| GEHC GE HealthCare Technologies Inc. compare | 9.33% |
| PHG Koninklijke Philips N.V. compare | 6.24% |
| Medical Devices industry median | −20.4% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on EW
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement